文献速递核素与放射性配体治疗放射性药物与辐射防护

225Ac-PSMA-617放射配体治疗中唾液腺内镜保护唾液腺的初步临床经验

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-08-27

11例转移性去势抵抗性前列腺癌患者在每周期225Ac-PSMA-617治疗前后接受唾液腺内镜扩张、生理盐水冲洗及泼尼松龙注射,口干问卷XQ评分从77.7±13.6降至42.7±14.8(p=0.003),XI评分从44.5±6.9降至25.8±12.8(p=0.003),无并发症;但多次治疗后唾液腺功能仍下降、口干仍存在。

要点

  • 11例患者双侧腮腺及双侧颌下腺均受放射性唾液腺炎累及并接受唾液腺内镜。
  • 唾液腺内镜后XQ评分由77.7±13.6降至42.7±14.8,XI由44.5±6.9降至25.8±12.8,均p=0.003。
  • 作者认为炎症与辐射直接效应均可能是口干的原因,需进一步研究。

核心结论

  • 唾液腺内镜联合扩张、生理盐水冲洗及类固醇注射对接受225Ac-PSMA-617放射配体治疗患者的唾液腺功能和生活质量有有益作用。
  • 即使有唾液腺内镜支持,多次治疗周期后唾液腺功能仍下降且口干仍存在,作者认为除炎症外辐射直接效应也是口干的可能原因。
  • 作者指出需要进一步研究以确定PSMA靶向α治疗的主要副作用。

研究设计与样本

  • 11例转移性去势抵抗性前列腺癌男性患者,平均年龄68.5岁(范围58-80岁)。
  • 在每周期225Ac-PSMA-617治疗前或后对双侧颌下腺及双侧腮腺行唾液腺内镜、扩张、生理盐水冲洗及类固醇(泼尼松龙)注射,由资深耳鼻喉科医生操作。
  • 采用口干问卷(XQ)和口干量表(XI)在干预前及干预后3个月评估健康相关生活质量。

主要发现

  • 全部11例患者双侧腮腺及双侧颌下腺均受放射性唾液腺炎累及并接受唾液腺内镜。
  • 患者唾液腺内镜后无并发症。
  • 唾液腺内镜后XQ评分由77.7±13.6降至42.7±14.8(p=0.003)。
  • 唾液腺内镜后XI评分由44.5±6.9降至25.8±12.8(p=0.003)。
  • 作者因患者数量有限仅报告倾向性。

局限性

  • 作者因患者数量有限仅报告倾向性。
  • 作者指出需要进一步研究以确定PSMA靶向α治疗的主要副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The main side effect of prostate-specific membrane antigen targeting alpha therapy (PSMA TAT) is dry mouth syndrome. Inflammation of the salivary glands and consequent reduced salivary function have been reported in patients after radioiodine therapy. The beneficial effects of sialendoscopy on radiation-induced inflammation in tissue are well known. Thus sialendoscopy with dilatation, saline irrigation and steroid injections (prednisolone) was performed before and after 225Ac-PSMA-617 TAT to reduce inflammatory effects in the salivary glands and to improve or prevent xerostomia. METHODS: Eleven men with metastatic castration-resistant prostate cancer (mean age 68.5 years, range 58-80 years) underwent sialendoscopy, dilatation, saline irrigation and steroid injection of both submandibular and both parotid glands before or after every cycle of 225Ac-PSMA-617 TAT. Sialendoscopy and steroid injection were performed by a senior ENT physician. Quality of life was evaluated using two health-related quality of life (HRQOL) questionnaires, the Xerostomia Questionnaire (XQ) and the Xerostomia Inventory (XI) before and 3 months after the intervention. RESULTS: In all 11 patients both parotid and both submandibular glands were affected by radiation sialadenitis and sialendoscopy was performed. The patients experienced no complications after sialendoscopy, and showed a significant improvement in HRQOL as measured using the XQ and XI. After sialendoscopy the XQ score decreased significantly from 77.7 ± 13.6 to 42.7 ± 14.8 (p = 0.003) and the XI score decreased from 44.5 ± 6.9 to 25.8 ± 12.8 (p = 0.003). Due to the limited number of patients we only report tendencies. CONCLUSION: Sialendoscopy with dilatation, saline irrigation and steroid injection had beneficial effects on salivary gland function and HRQOL in patients undergoing 225Ac-PSMA-617 RLT. However, even with sialadenoscopic support after multiple cycles of TAT, salivary gland function was reduced and xerostomia was present. Therefore, not only inflammation but also the direct effect of radiation is a putative cause of dry mouth. Further research is necessary to determine the main side effects of PSMA TAT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rathke H, Kratochwil C, Hohenberger R, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2018. PMID: 30151743. doi:10.1007/s00259-018-4135-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。